These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2161034)

  • 21. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).
    Jacobson MA; Adler SP; Sinclair E; Black D; Smith A; Chu A; Moss RB; Wloch MK
    Vaccine; 2009 Mar; 27(10):1540-8. PubMed ID: 19168107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.
    Schleiss MR
    J Clin Virol; 2008 Mar; 41(3):224-30. PubMed ID: 18060834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection.
    Bourne N; Schleiss MR; Bravo FJ; Bernstein DI
    J Infect Dis; 2001 Jan; 183(1):59-64. PubMed ID: 11087203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
    Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
    J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine strategies against human cytomegalovirus infection.
    Zhong J; Khanna R
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):449-59. PubMed ID: 17547509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccines for the prevention of human cytomegalovirus infection.
    Plotkin SA; Starr SE; Friedman HM; Gonczol E; Brayman K
    Rev Infect Dis; 1990; 12 Suppl 7():S827-38. PubMed ID: 2173112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
    Zhang C; Pass RF
    Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Lancet; 1984 Mar; 1(8376):528-30. PubMed ID: 6142252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
    Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
    J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization strategy for prevention of congenital cytomegalovirus infection.
    Pass RF
    Infect Agents Dis; 1996 Oct; 5(4):240-4. PubMed ID: 8884369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates.
    Sachs GW; Simmons RL; Balfour HH
    Vaccine; 1984 Sep; 2(3):215-8. PubMed ID: 6099649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoprophylaxis of experimental cytomegalovirus infection.
    Minamishima Y
    Ann Microbiol (Paris); 1977 Oct; 128(3):399-407. PubMed ID: 203216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The status of cytomegalovirus vaccine.
    Starr SE; Friedman HM; Plotkin SA
    Rev Infect Dis; 1991; 13 Suppl 11():S964-5. PubMed ID: 1664136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human cytomegalovirus vaccine: time to look for alternative options.
    Khanna R; Diamond DJ
    Trends Mol Med; 2006 Jan; 12(1):26-33. PubMed ID: 16337831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA vaccines against cytomegalovirus: current progress.
    Temperton NJ
    Int J Antimicrob Agents; 2002 Mar; 19(3):169-72. PubMed ID: 11932137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
    Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
    J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
    Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
    J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination against human cytomegalovirus with live virus.
    Plotkin SA; Friedman HM; Starr S; Fleisher G
    Dev Biol Stand; 1982; 52():373-9. PubMed ID: 6299846
    [No Abstract]   [Full Text] [Related]  

  • 39. [Congenital cytomegalic disease. Current possibilities and prospects of prevention].
    Nardiello S; Galanti B
    Clin Ter; 1990 Sep; 134(5):281-7. PubMed ID: 2178077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination of pediatric nurses with live attenuated cytomegalovirus.
    Fleisher GR; Starr SE; Friedman HM; Plotkin SA
    Am J Dis Child; 1982 Apr; 136(4):294-6. PubMed ID: 6280490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.